Key result
Outpatient treatment of acute pulmonary embolism with direct oral anticoagulants resulted in 0% recurrent VTE, 0.4% major bleeding, and 0.4% mortality over 6 months of follow-up.
Why the study?
Does outpatient treatment with direct oral anticoagulants prevent recurrent VTE and bleeding in selected patients with acute pulmonary embolism?
Cohort (n=245)
Yes
Does outpatient treatment with direct oral anticoagulants prevent recurrent VTE and bleeding in selected patients with acute pulmonary embolism?
Outpatient treatment of acute pulmonary embolism with direct oral anticoagulants is effective and safe in selected low-risk patients, with no VTE recurrences and very low bleeding rates at 6 months.
Answers are grounded in this paper and cite their sources.
May support outpatient DOAC use in selected low-risk PE; leaves open need for RCTs before practice change.
Anticoagulant treatment of acute pulmonary embolism (PE) has traditionally been hospital-based. The lesser need for monitoring with the increasingly used direct acting oral anticoagulants (DOAC) in comparison to warfarin potentially facilitates outpatient treatment of PE with these drugs. This study aimed to evaluate efficacy and safety of outpatient treatment of PE with DOAC. We extracted data from the Swedish quality registry for patients on oral anticoagulation (AuriculA) for all 245 patients in the southernmost hospital region in Sweden (1.3 million inhabitants) selected for outpatient treatment with of PE with DOAC during 2013-2015. Comorbidites, risk factors, and simplified pulmonary embolism severity index were evaluated at baseline, and death, recurrent venous thromboembolism (VTE), and bleeding was recorded during 6 months of follow-up. Outpatient treatment was defined as discharge from the emergency department within 24 h. During 6 months of follow-up, one patient died during DOAC therapy, the cause of death was unrelated to VTE. No VTE recurrences occured, whereas, one patient experienced major bleeding, and five patients experienced minor bleedings. Outpatient treatment of PE with DOAC is efficient and safe in selected patients.
No takes yet. Share an insight, caveat, or question.
Ghazvinian et al. (2018) conducted a cohort in Pulmonary embolism (n=245). Outpatient treatment with direct oral anticoagulants (DOAC) was evaluated on Recurrent venous thromboembolism (VTE) at 6 months. Outpatient treatment of acute pulmonary embolism with direct oral anticoagulants resulted in 0% recurrent VTE, 0.4% major bleeding, and 0.4% mortality over 6 months of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: